Cardiac monitoring in HER2-positive patients on trastuzumab treatment by Bouwer, N.I. (Nathalie) et al.
lable at ScienceDirect
The Breast 52 (2020) 33e44Contents lists avaiThe Breast
journal homepage: www.elsevier .com/brstReviewCardiac monitoring in HER2-positive patients on trastuzumab
treatment: A review and implications for clinical practice
Nathalie I. Bouwer a, b, Agnes Jager c, Crista Liesting a, Marcel J.M. Kofflard a,
Jasper J. Brugts d, Jos J.E.M. Kitzen b, Eric Boersma d, Mark-David Levin b, *
a Department of Cardiology, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the Netherlands
b Department of Internal Medicine, Albert Schweitzer Hospital, Albert Schweitzerplaats 25, 3300 AK, Dordrecht, the Netherlands
c Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, the Netherlands
d Department of Cardiology, Erasmus MC Thoraxcenter, Dr. Molewaterplein 40, 3000 CA, Rotterdam, the Netherlandsa r t i c l e i n f o
Article history:
Received 11 October 2019
Received in revised form
17 March 2020
Accepted 13 April 2020
Available online 16 April 2020
Keywords:
Trastuzumab
Cardiotoxicity
Cardiac monitoring
Biomarkers
Speckle tracking echocardiography* Corresponding author.
E-mail address: m-d.levin@asz.nl (M.-D. Levin).
https://doi.org/10.1016/j.breast.2020.04.005
0960-9776/© 2020 The Authors. Published by Elseviera b s t r a c t
Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth
factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by car-
diotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence ranging
from 3 to 27% depending on variable factors. Early identification of patients at increased risk of
trastuzumab-induced myocardial damage is of great importance to prevent deterioration to irreversible
cardiotoxicity. Although current cardiac monitoring with multi gated acquisition (MUGA) scanning and/
or conventional 2D-echocardiography (2DE) have a high availability, their reproducibility are modest,
and more sensitive and reliable techniques are needed such as 3D-echocardiography (3DE) and speckle
tracking echocardiography (STE). But which other diagnostic imaging modalities are available for pa-
tients before and during trastuzumab treatment? In addition, what is the optimal frequency and duration
of cardiac monitoring? At last, which biomarker monitoring strategies are currently available for the
identification of cardiotoxicity in patients treated with trastuzumab?
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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About 20% [1] of breast tumors show overexpression of human
epidermal growth factor receptor 2 (HER2), which is caused by
amplification of the HER2-oncogene [2]. HER2 is a transmembrane
receptor with an intra- and extracellular domain which plays an
important role in normal growth and in the development of various
tissues [3,4]. In HER2-overexpressing breast tumors, HER2 is often
the main driver through which rapid growth occurs resulting in a
poor prognosis [5,6].
Trastuzumab is a humanized monoclonal antibody targeting the
extracellular domain of HER2. After binding to the extracellular
domain of HER2, trastuzumab inhibits the intracellular tyrosine
kinase activity and thereby inhibiting the proliferation of HER2-
positive breast cancers resulting in cell death. Therefore, trastuzu-
mab is highly effective in patients with HER2-overexpressing breast
cancer. Large randomized phase 3 trials showed that addition of
one year of trastuzumab treatment to adjuvant chemotherapy
impressively improves overall survival by 24e33% in these patients
[7,8]. Likewise, addition of trastuzumab to chemotherapy in first
line setting for advanced breast cancer increases the overall sur-
vival by 5e8 months [8,9] and even up to 15 months when com-
bined with pertuzumab and docetaxel in first line relapse setting
[10].
HER2 is also physiologically expressed on myocytes. Although
HER2 is not overexpressed on myocytes, trastuzumab treatment is
associated with an increased risk of a decrease in left ventricular
ejection fraction (LVEF) which can lead to clinically manifest heart
failure. Risk factors for trastuzumab-induced cardiotoxicity are
older age (>65 years), hypertension, diabetes mellitus, obesity (BMI
>30 kg/m2), previous anthracycline exposure, short time between
anthracycline treatment and anti-HER2 treatment, previous radi-
ation therapy and compromised cardiac function before treatment
[11e15]. Because of the impressive prognostic impact of trastuzu-
mab treatment, a sizeable number of patients who survive HER2-
positive breast cancer due to trastuzumab are at risk for devel-
oping cardiotoxicity. Hence, strategies tomonitor and prevent long-
term disabling cardiotoxicity are of utmost importance.
Although trastuzumab-induced cardiotoxicity is believed to be
reversible, some reports suggest that in about 50% it is only partly
reversible and in 12e29% it is even irreversible [16e19]. It should be
mentioned that these patients in these reports were all pre-treated
with anthracyclines, which is a known cause of irreversible car-
diotoxicity [20]. Early detection of trastuzumab-derived car-
diotoxicity might prevent both reversible and possibly irreversible
effects on the heart function [21], because early discontinuation of
trastuzumab and/or early implementation of cardio-protective
therapies positively impact cardiac outcome [22,23]. Importantly,
most patients successfully restart trastuzumab treatment after
transient LVEF impairment as it has been shown that trastuzumab
does not induce permanent myocyte apoptosis as opposed to
anthracyclines that induce cardiomyocyte apoptosis via oxidative
stress and free radical formation [24,25]. However, recent studies in
human cardiac cell cultures and in mice indicate that trastuzumab
can induce myocyte apoptosis leading to irreversible cardiotoxicity[26e28].
The exact mechanism of trastuzumab-induced cardiotoxicity is
still unknown. Some studies show that trastuzumab inhibits car-
diomyocyte repair by blocking neuregulin-1 and the HER2 down-
stream pathwaywhich is required for cardiac repair, especially after
anthracycline treatment [29,30]. Another study showed that tras-
tuzumab inhibits topoisomerase IIB, similar to anthracycline,
leading to increased reactive oxygen species formation and
sequential apoptosis [31]. More research is needed to clearly un-
derstand the mechanism of trastuzumab-induced cardiotoxicity.
Thus, monitoring of LVEF during trastuzumab is important.
However, current cardiac monitoring techniques have some
important limitations. First, LVEF measurements vary between the
different techniques used in clinical practice and the reproduc-
ibility of many techniques are questionable. Second, LVEF reflects
the functional status of the left ventricle (LV) and a LVEF decline is
only observed once functional impairment already has occurred.
Third, the LVEF is preload and afterload dependence and can sub-
stantially change based on different loading conditions [32].
Therefore, for the early detection of injured myocardial cells more
sensitive diagnostic tools are required.
In this review, we present an overview and critical appraisal of
the state-of-the-art with respect to the role, frequency and duration
of cardiac imaging and biomarker monitoring strategies in
trastuzumab-treated HER2-positive breast cancer patients.1.1. What is the incidence of cardiotoxicity of trastuzumab?
The incidence of cardiotoxicity due to trastuzumab treatment
varies according to the definition used, whether or not trastuzumab
is combined with anthracyclines (sequential or concomitant) and/
or other HER2-blocking agents such as pertuzumab and lapatinib
which have similar to lower risk of cardiotoxicity (Table 1), treat-
ment duration, and type of imaging technique used. Most trials use
the definition of cardiotoxicity related to cancer therapeutics
defined by the European Society of Cardiology (ESC) as a decrease
in LVEF of >10%-points to a value below 50% [33]. However,
consensus on the definition for cardiotoxicity is missing. In this
review, the term cardiotoxicity refers to myocardial damage related
to anticancer pharmacological therapies.
Trastuzumab monotherapy in adjuvant setting has a relatively
low incidence of trastuzumab-related cardiotoxicity of 3e7%,
however when given concomitantly with doxorubicin and cyclo-
phosphamide the reported incidence of cardiotoxicity can increase
up to 27% in clinical trials [34]. This seems due to cumulative
toxicity of simultaneous administration of these agents as the
repair of oxidative stress induced by anthracycline is hampered by
trastuzumab blocking the HER2 downstream pathway that is
required for cardiac repair [39]. Interestingly, concomitant use of
trastuzumab and epirubicin appears to be far less cardiotoxic
[40,41], resulting in an increased use even in the neo-adjuvant
setting. Although both agents are anthracyclines, it remains un-
known why epirubicin, a 4‘-epimer of doxorubicin, is less car-
diotoxic [42].
An important issue to address is whether these incidence rates
Table 1
Incidence of cardiotoxicity varying per chemotherapeutic and definition used.
Exposed chemotherapeutic Incidence Cardiotoxicity definition used:
Trastuzumab monotherapy [34] 3e7%0 CREC criteria:
1. Cardiomyopathy characterized by a decrease in cardiac LVEF global or severe in the septum
2. Symptoms of CHF
3. Associated sign of CHF, including S3 gallop, tachycardia or both
4. Symptomatic decline in LVEF >5% to an LVEF <55% or an asymptomatic LVEF decline of >10% to an LVEF
<55%.
Trastuzumab with previous anthracycline:
epirubicin [117]
4% CHF
Trastuzumab with previous anthracycline:
doxorubicin [34]
13% CREC criteria as mentioned above.
Trastuzumab, epirubicin and cyclophosphamide
[118]
5% Symptomatic heart failure NYHA class III or IV associated with an absolute decrease in LVEF of more than
10% points to less than 50%
Trastuzumab, doxorubicin and cyclophosphamide
[34]
27% CREC criteria as mentioned above.
Trastuzumab þ HER2 inhibitor: pertuzumab [119] 4% LVEF of less than 50% and a decrease of more than 10% from baseline
Trastuzumab þ intracellular HER2-kinase inhibitor:
lapatinib [120]
3% LVEF of less than 50% and a decrease of more than 10% from baseline or congestive heart failure or
myocardial ischemia
Abbreviations: CREC, Cardiac Review and Evaluation Committee; LVEF, left ventricular ejection fraction; CHF, congestive heart failure; NYHA, New York Heart Association;
HER, human epidermal growth factor receptor.
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with comorbidities and with a history of cardiac disease or heart
failure who are excluded in most clinical trials. Population based,
retrospective studies indicate that the rates and impact of
trastuzumab-induced cardiotoxicity might be higher in ‘real world’
patients than mentioned in clinical trials [43]. For example, the 5-
year cumulative incidence of cardiotoxicity in older patients
(aged >75 years) treated with anthracycline and trastuzumab was
40.7% compared to incidence of 27% found in a clinical trial [34,44].
Therefore, the incidence rates of these selected patients from pro-
spective clinical trials cannot be unconditionally extrapolated to
‘real world’ patients.
2. Which diagnostic imaging modalities are currently
available for patients on trastuzumab treatment?
2.1. MUGA scan
Multi gated acquisition (MUGA) scanning is a frequently usedTable 2
Various imaging techniques for the detection of cardiotoxicity.
Imaging technique Advantages
Echocardiography
 Two-dimensional
Wide availability
Lack of radiation exposure
Cost-effective
Assessment of myocardial structures
 Three-dimensional High accuracy in detecting small LVEF changes
High reproducibility compared to 2DE
Lack of radiation exposure
Cost-effective
Assessment of myocardial structures
Speckle tracking
echocardiography
GLS for subclinical identification of cardiotoxicity
Relatively low angle dependence
Same advantages as echocardiography
Cardiac magnetic resonance High accuracy
High reproducibility
Assessment of myocardial structures/myocardial fib
Helps identifying the cause of cardiotoxicity
Low radiation exposure
MUGA scanning Availability
Few technical limitations
Abbreviations: LVEF, left ventricular ejection fraction; MUGA, multi-gated acquisition simaging modality for evaluation of LVEF evolvement during
chemotherapy and trastuzumab therapy. MUGA scanning is a
minimal-invasive nuclear imaging technique using 99mTc-erythro-
cyte labeling. It is capable to measure systolic-diastolic changes in
radioactivity within the LV to calculate the blood flow leaving the
LV, i.e. the LVEF. This method has a high availability and few tech-
nical limitations as it can be done in all patients without limitations
due to obesity, poor acoustic windows or presence of cardiac de-
vices such as pacemakers or defibrillators (see Table 2) [45].
Nevertheless, major limitations of measuring the LVEF with MUGA
scans are the questionable accuracy, modest reproducibility, cu-
mulative radiation exposure of serial monitoring, and its limited
information on structural cardiac dysfunction [46]. The accuracy of
MUGA scans remains dubious as contemporary MUGA scans are
performed with a large-field-of-view, two head system gamma
cameras that do not allow optimal patient positioning [47]. In
addition, assessment of the LVEF with MUGA scans has shown to
have large inter- and intra-observer variations and varies between
hospital centers and software packages computer processingLimitations
High inter-observer variability
Dependent on image quality
Insensitive to detect small LVEF changes
Dependent on image quality and operator experience
Low availability in cancer centers
Inter-vendor variability
Technical requirements
Dependent on image quality
Low temporal resolution
Different results due to different algorithms
rosis
Limited availability
High costs
Low temporal resolution
Patients adaptation (claustrophobia, breath hold and long acquisition times)
Limited in patients with metallic prosthetics
High cumulative radiation exposure
Limited informative on cardiac structures
Lower accuracy
can.
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[48,49].
Besides this, the radiation exposure from a single MUGA scan is
approximately 10 mSv per scan, which is three times the average
yearly background radiation [46]. Thus, serial monitoring of the
LVEF results in an unacceptable high cumulative exposure, while
most breast cancer patients already have an increased radiation
exposure due to other imaging modalities used for staging of the
breast cancer. Fortunately, new 3D MUGA cameras allow obtaining
the LVEF with less than 2 mSv [50], but these cameras are not yet
implemented in daily clinical practice.
2.2. Echocardiography, ultrasound of the heart
Cardiac evaluation before, during and after trastuzumab treat-
ment can also be performed with conventional echocardiography.
Advantages of echocardiography over MUGA are its lack of radia-
tion exposure and the possibility to assess the complete cardiac
structure. Disadvantages of echocardiography are the high inter-
observer variability, dependency on image quality,insensitivity to
detect small LVEF changes and false positive rate of cardiotoxicity of
3.6% [51].
Three-dimensional echocardiography (3DE) has a better accu-
racy in detecting LVEF below the lower limit of normal and a better
reproducibility than the conventional two-dimensional echocar-
diography (2DE) biplane Simpson method [52,53]. However,
applicability of 3DE in the oncologic setting is limited, because it
remains dependent on availability in the different hospitals, re-
quires adequate image quality (more so than 2DE) and operator
experience (Table 2).
3. Which new diagnostic imaging modalities are available for
patients on trastuzumab treatment?
3.1. Speckle tracking echocardiography
A sensitive and promising diagnostic modality is the so-called
strain imaging with speckle tracking echocardiography (STE) [47].
Dedicated STE software is capable to track the movement of
speckles, which are tracking points that are placed automatically on
the LVwall in the conventional 2D-echocardiographic images and
reflect the movement of the different segments of the heart [54].
Additionally, STE can also be applied in 3DE and CMR, which is
currently not frequently observed in clinical practice [55].
Strain is a method for measuring regional or global myocardial
deformation, i.e. the proportional change in dimension of the heart
in relation to the original dimension of the heart. Consequently,
strain measurement with STE is capable to quantify myocardial
function regionally, and to identify subtle and subclinical LV
dysfunction. New parameters for myocardial function assessment
emerged with the introducing of STE, including global longitudinal
strain (GLS), global circumferential strain (GCS) and global radial
strain (GRS). The GLS reflects the longitudinal contraction of the
myocardium, and thus represents the global left ventricular func-
tion [56,57]. The GCS reflects the circumferential contraction of the
myocardium and is expressed as a negative percentage value,
likewise as the GLS, as the myocardium shortens during contrac-
tion. Finally, the GRS reflects the radial contraction of the myocar-
dium, i.e. the lengthening of the myocardium and is expressed as a
positive percentage. In the general population, GLS has a better
prognostic value than 2DE-LVEF to predict major adverse cardiac
events including hospitalisation due to heart failure and cardiac
death during an average follow-up of 27 months [58].
In patients with HER2-positive breast cancer treated with
anthracyclines and trastuzumab an GLS decline from baselinemeasured with STE precedes an LVEF decline measured with 2DE
[59e62]. The systematic review of Thavendiranathan et al.
demonstrated that an early relative reduction in GLS of 10% dur-
ing therapy is very likely to be indicative for cardiotoxicity defined
as an LVEF decline of 5% to an LVEF <55% or symptomatic heart
failure [63]. In addition, the expert consensus document of the
American Society of Echocardiography (ASE) and European Asso-
ciation for Cardiovascular Imaging (EACVI) suggests that a relative
change in GLS >15% from baseline is likely to indicate of clinically
meaningful cardiotoxicity [47]. Likewise, a recent meta-analysis
showed that the absolute GLS cutoff values, ranging from 21%
to 14%, can be useful to stratify patients at high risk of developing
cardiotoxicity which is important in patients without baseline
cardiac imaging [64]. Although a reduction in GLS is correlatedwith
an reduction in LVEF [59e62], little is known about the predictive
value of an impaired GLS on long-term cardiotoxicity, the optimal
GLS cutoff value and the development of an impaired GLS to
symptomatic heart failure. Importantly, STE has some disadvan-
tages including the need for high-resolution image quality and the
insufficient standardization of measurements by different echo-
cardiographic vendors resulting in non-comparative results [33].
Thus, the role of speckle tracking echocardiography in early
detection of subclinical cardiotoxicity in the oncologic setting
seems promising. However, these findings should be validated in
larger prospective multicenter studies. The results of the SUCCOUR
trial, which is a currently ongoing randomized controlled trial that
randomly allocates patients on cardiotoxic cancer treatment to an
GLS-guided treatment strategy or LVEF-guided treatment strategy,
are urgently awaited in this respect [65].3.2. Cardiac MRI
Cardiac magnetic resonance (CMR) imaging is often considered
the gold standard for evaluation of the cardiac structure and cardiac
function. Besides quantification of cardiac dysfunction, CMR pro-
vides insight in its likely cause, as it provides information about the
cardiac structure and myocardial fibrosis because of its high reso-
lution [66]. Other advantages of CMR are its high reproducibility
and accuracy. The major limitations of CMR however, are its high
costs and therefore limited availability, the reason why CMR is
currently not used for serial monitoring of the LVEF.3.3. Comparison of imaging modalities and summary
LVEF assessments with MUGA scanning, echocardiography and
CMR show poor correlation [67]. Discordance between MUGA and
CMR in measuring the LVEF particularly occurred in small left
ventricles, small hearts and hearts with a history of atrial fibrilla-
tion [68]. Furthermore, 2DE is suggested to overestimate the mean
LVEF with 5% and has a lower sensitivity in detecting LVEF values
less than 50% compared to CMR [69]. Possible false-positive results
due tomeasuring the LVEF with echocardiography or MUGA cannot
be excluded. In contrast to conventional 2DE, 2D-STE is highly
correlated with CMR in measuring the LVEF [70]. Comparisons of
2D-STE with 3D-STE showed that 3D-STE had lower inter- and
intra-observer variability [71]. Therefore, it is recommended to use
the same monitoring modality for baseline and follow-up LVEF
assessments [33,72].
Concluding, not 2DE or MUGA scanning but 3DE seems most
suitable for cardiac monitoring of patients on trastuzumab due to
the high reproducibility, high accuracy and the ability to assess the
complete cardiac structure. In addition, strain measurement with
STE seems promising to detect myocardial damage in an early stage
compared to LVEF measurement.
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monitoring for patients on trastuzumab?
Another important question for clinicians who treat patients
with trastuzumab is: what is the optimal frequency and duration of
cardiac monitoring? The US Food and Drug Administration (FDA)
label of trastuzumab recommends, based on protocols in clinical
trials, LVEF monitoring prior to initiation of trastuzumab and every
3 months during and upon completion of adjuvant trastuzumab
treatment. After completion of 1 year trastuzumab in the adjuvant
setting, LVEF monitoring every 6 months for at least 2 years is
recommended. If trastuzumab is withheld for significant LV cardiac
dysfunction, cardiac monitoring should occur monthly. These rec-
ommendations have been adopted into clinical practical guidelines
by the European Society of Medical Oncology (ESMO) [73], Euro-
pean Society of Cardiology (ESC) [33] and American Society of
Clinical Oncology (ASCO) [11]. The ESC differentiates between low
risk patients (normal baseline echocardiogram and no clinical risk
factors) for whom cardiac monitoring every 3 months is advised
and high risk patients (abnormal baseline echocardiography and
clinical risk factors) for whom even more frequent cardiac moni-
toring is advised. Interestingly, it should be noted that the ASCO
recommends cardiac monitoring 6e12 months after completion of
therapy in high risk patients. Lastly, the ESMO recommends cardiac
monitoring infrequently in the absence of symptoms during tras-
tuzumab for advanced breast cancer. As these guidelines are mainly
based on expert consensus rather than trial data and as they have
not been prospectively validated, the optimal frequency of cardiac
monitoring during trastuzumab therapy has not been established
yet.
Table 3 gives an overview of frequency and duration of cardiac
monitoring during and after trastuzumab treatment in current
literature. In cohort studies, cardiac monitoring was most often
performed every 3e4 months in the first year of trastuzumab
treatment for early-stage breast cancer. However, after discontin-
uation of trastuzumab for early-stage breast cancer, cardiac moni-
toring was only observed in a few studies (4 out of the 13). During
trastuzumab treatment for advanced-stage disease, cardiac moni-
toring was performed every 3e8 months up until 2 years of tras-
tuzumab treatment. After 2 years of trastuzumab treatment,
cardiac monitoring was only observed in 1 study [74]. In addition,
in randomized controlled trials, cardiac monitoring was performed
every 3e6 months during the first year of trastuzumab treatment
or even 2 years in some studies [9,10,75,76]. After discontinuation
of trastuzumab, cardiac monitoring was performed in the majority
of the studies (10 out of the 16), which was not often observed in
the cohort studies. Studies investigating cardiac monitoring after
discontinuation of trastuzumab showed a low cumulative inci-
dence of cardiotoxicity, defined as LVEF decline >10%-points from
baseline to LVEF <50% or <55% or New York Heart Association
(NYHA) class III or IV, of 0.5e5.8% [19,77,78]. However, conflicting
results are found regarding the development of heart failure 2 years
after starting trastuzumab. An 2-fold increased risk of late heart
failure of trastuzumab compared to chemotherapy alone has been
found in one study [79], whereas other studies did not find excess
risk of lateheart failure after trastuzumab discontinuation [80,81].
Concluding, cardiac monitoring, predominantly with echocardiog-
raphy or MUGA, occurs most often every 3 months during trastu-
zumab treatment for early-stage breast cancer, and more
infrequently during trastuzumab treatment for advanced-stage
breast cancer. Based on current knowledge, the additional value
of frequent cardiac monitoring after discontinuation of trastuzu-
mab has not been confirmed. It would be reasonable to consider a
less frequent schedule or omission of monitoring after discontin-
uation of trastuzumab.5. What is the role of cardiac biomarkers in detecting
cardiotoxicity?
5.1. Troponin
Cardiac troponin regulates the contractile element actin and
myosin. It is a proteinwith three subunits: T, I and C. Troponin I and
troponin T are exclusively present in myocardial cells, whereas
troponin C is also present in slow-twitch skeletal muscles [101].
Elevated cardiac troponin is indicative of myocardial damage due to
for instance acute coronary syndrome or acute myocarditis
[102,103]. Therefore, it can be expected that myocardial damage
due to trastuzumab therapy can lead to increased troponin levels
[104].
Studies measuring conventional troponin showed conflicting
results (Table 4). Some studies, in which patients received anthra-
cycline and trastuzumab, demonstrate a relationship between
increased troponin values during trastuzumab treatment and an
LVEF decline 105,106. In particular, patients with increased
troponin values after anthracycline treatment had higher risk of
developing cardiotoxicity than those with stable (low) values [107].
However, most studies did not demonstrate this relationship in
patients with trastuzumab-based chemotherapy [108e113]. One of
these studies concluded that elevation of troponin preceded
changes in LVEF, but not particularly predicted clinical cardiac
dysfunction [112]. The most likely explanation for the conflicting
results is the timing of conventional troponin measurement [114]
and the preceding treatment with anthracyclines [107,115,116].
However, the studies that used high-sensitivity (hs) troponin
assays demonstrated a relationship between increased hs-troponin
values and LVEF [59,60,116,[117]. It is plausible that hs-troponin
assays have a better range for detection of cardiac dysfunction in
patients treated with trastuzumab than conventional troponin as-
says. Lastly, sex-specific cut-off values of troponin assays have to be
taken into account [121].
5.2. NT-proBNP
The N-terminal fragment of the pro-hormone brain natriuretic
peptide (BNP), NT-proBNP, is the inactive N-terminal fragment of
the biologically active hormone BNP and is secreted by myocytes in
response to increased cardiac transmural pressure. NT-proBNP has
shown to be useful as a diagnostic and prognostic indicator of heart
failure in multiple clinical settings, as summarized in the system-
atic review by Santaguida et al. [122].
Increased NT-proBNP values have been associated with car-
diotoxicity in patients treated with anthracyclines [118,123,124].
Interestingly, another study demonstrated that in patients treated
with anthracyclines and trastuzumab the risk of LVEF decline
increased by almost 30% for each 10 ng/dL increase in NT-proBNP
during trastuzumab treatment [117]. However, elevated NT-
proBNP values are also seen in patients receiving trastuzumab
with a normal LVEF [125]. Furthermore, not every study demon-
strated an association between NT-proBNP and cardiotoxicity dur-
ing anthracycline and trastuzumab (Table 4) [59,60,106,111,113,119].
This is possibly due to the wide biological variation (analytical and
intra-individual) of natriuretic peptides levels due to secretory
burst and rapid turnover [126].
5.3. CRP
C-reactive protein (CRP) is a marker of inflammation which
plays a role in atherosclerosis and acute coronary syndrome
[127,128]. It has also been demonstrated to be of prognostic value in
patients with chronic heart failure [129]. Therefore, it could be
Table 3
Overview of studies in which cardiotoxicity was monitored during and after trastuzumab treatment.
Study N Stage Treatment Cardiac
monitoring
modality
During trastuzumab treatment Monthly
interval
After trastuzumab Cardiotoxicity
incidence
Definition of
cardiotoxicity
Additional remarks
Baseline 0e3
months
3e6
months
6e12
months
1e2
years
>2
years
0e3
months
3e6
months
>6
months
Cohort
Tarantini
(2012) [82]
499 Early AC þ Tax þ T Echo þ þ þ þ NA NA 3 e e e 27% LVEF decline >10%
or <50% or heart failure
Piotrowski
(2012) [83]
253 Early AC þ Tax þ T 2DE þ þ þ þ NA NA 3 þ þ 21% LVEF decline >15%,
or >10% to <50%
or signs of
heart failure
Cochet
(2011) [84]
118 Early AC þ Tax þ T Radionuclide
angiography
þ þ þ þ NA NA 3 e e e 15% Asymptomatic LVEF
decline >10%
Dent
(2012) [85]
48 Early AC þ T Echo and MUGA þ þ þ þ NA NA 3 e e e 59% LVEF decline 10
or heart failure
Repeat monitoring
as clinically indicated
Matos
(2016) [86]
92 Early AC þ T 2DE þ e þ þ NA NA 4 e e e 21% LVEF decline >10%
or signs of heart failure
Seferina
(2016) [87]
230 Early AC þ Tax þ T Unknown þ þ þ þ NA NA 3 e e e 13% LVEF decline >10% to <50%
Visser
(2016) [88]
171 Early Chemo þ T MUGA þ
76%a
þ
53%a
þ
40%a
þ
30%a
NA NA 3 e þ
9%a
þ
1%a
NA NA
Chavez
(2015) [89]
2203 Early Chemo þ T Echo or MUGA þ
79%a
þ
87%a
þ þ NA NA 4(43%)a þ þ e NA NA
Lidbrink
(2019) [90]
3733 Early AC þ Tax þ T Echo, MUGA,
CMR or other
þ þ þ NA NA 3 e þ þ 3% Symptomatic heart failure Until 2
years after stop T
Grazziotin
(2017) [91]
109 Early/
advanced
AC þ Tax þ T Echo þ þ þ þ e e 3e4 e e e 53% LVEF decline >10% or
<50% or heart failure
Frequency depending
on physicians
Sun
(2016) [74]
105 Early/
advanced
AC þ T Echo þ þ þ þ þ þ 3 NA NA
Davis
(2016) [92]
43 Early/
advanced
AC þ Tax þ T Echo þ
35%a
e e þ- þ- e 8 e e e 18% CREC criteria (Table 1)
Extra
(2010) [93]
623 Advanced AC þ T Unknown þ
57%a
þ/ þ/ þ/ þ e No e e e 3% Heart failure
RCT
Perez
(2008) [78]
2148 Early AC þ P
AC þ P þ T
Echo or MUGA þ þ þ þ NA NA 3 þ þ e 3%
3%
Cardiac event assessed
by 3 cardiologists
Suter
(2007) [94]
3386 Early AC þ T Echo or MUGA þ þ þ þ NA NA 6 þ þ þ 7% LVEF decline >10% to <50%
Romond
(2005) [7]
3351 Early AC þ P
AC þ P þ T
Echo or MUGA þ þ þ þ NA NA NA e e e 4%
3%
NYHA III/IV heart
failure after 3 years
Joensuu
(2009) [72]
232 Early Tax þ FEC þ T
V þ FEC þ T
(Isotope) echo þ e þ e NA NA NA e e þ 1% Heart failure Up to 5
years after start T
Tan-Chiu
(2005) [19]
2043 Early AC þ P
AC þ P þ T
MUGA scan þ e þ þ NA NA NA e þ e 4% NYHA III/IV heart failure
after 3 years
Repeat monitoring
as clinically indicated
Piccart-Gebhart
(2005) [95]
5081 Early AC þ T Echo or MUGA þ þ þ þ NA NA 6 e þ þ 1% Symptomatic heart failure Up to 5
years after start T
Cameron
(2017) [77]
5102 Early AC þ Tax þ T Echo or MUGA þ þ þ þ NA NA 6 e þ þ 1% NYHA III/IV and LVEF
decline >10% to <50%
3
years after start T
annually to 10
years
Gianni
(2010) [96]
235 Early AC þ Tax þ T Echo or MUGA,
þ ECG
þ e e e NA NA NA þ e e 2% NYHA III/IV heart failure
Slamon
(2011) [97]
3222 Early ACT-T þ T
TCH
Echob or MUGA þ þ e þ NA NA NA e e þ 19%
11%
Heart failure and LVEF
decline >10%
Up to 5
years after start of T
Swain
(2015) [10]
808 Advanced Pe þ T þ Tax
T þ Tax
Echo or MUGA s þ þ þ þ þ þ 3 þ þ þ 6%
7%
LVEF decline >10% to <50% Up to 1.5 year after
stop of T
296 Advanced Echo or MUGA þ þ þ þ þ þ 1 þ e e 5% LVEF decline <20%
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Blackwell
(2010) [75]
AC þ Tax þ T
T þ L
Marty
(2005) [9]
186 Advanced AC þ T
T þ Tax
Echo or MUGA þ þ þ þ þ þ 3 e e e 2% Symptomatic heart failure
Von Minckwitz
(2009) [98]
156 Advanced T
T þ C
Echo þ e e e e e NA e e e 5% NYHA class III/IV
heart failure
Repeat monitoring
as clinically indicated
Gasparini
(2007) [99]
123 Advanced T
T þ P
Echo or MUGA þ þ þ þ e e 3 e e e 0% Symptomatic heart
failure
Kaufman
(2009) [76]
207 Advanced T
T þ A
Unknown e þ þ þ þ e 2
months
e e e 14% Cardiac events: heart
failure, LVEF decline
or discontinuation of T
Müller
(2018) [100]
19 Advanced T Echo or MUGA e e e e e e No 0% NYHA class II-IV Monitoring as
clinically indicated
Abbreviations: AC, anthracyclineþ cyclophosphamide; T, trastuzumab; Tax, taxanes; P, paclitaxel; D, doxorubicin; V, vinorelbine; FEC, fluorouracil, epirubicin, docetaxel; Pe, pertuzumab; ACT-T, doxorubicin, cyclophosphamide
followed by docetaxel; TCH, doxetaxel, carboplatin and trastuzumab; L, lapatinib; C, capecitabine; A, anastrozole; Echo, echocardiography; MUGA, multi-gated acquisition scan; CMR, cardiac magnetic resonance imaging; NA,
not applicable; LVEF, left ventricular ejection fraction; RCT, randomized controlled trial; CREC, Cardiac Review and Evaluation Committee; NYHA, New York Heart Association.
a Adherence rate of cardiac monitoring.
b Echocardiography is preferred cardiac monitoring method, same method is advised. þ cardiac monitoring performed, - monitoring not performed.
Table 4
(Cardiac) biomarkers for identification of cardiotoxicity.
Type cardiac
biomarker
Study Number of
patients
Chemotherapy Time point(s) indicative of
cardiotoxicity
Detection of
cardiotoxicity?
Definition cardiotoxicity:
Troponin T Fallah-rad
(2011) [108]
42 AC þ T 12 months after initiation of T
treatment
e Absolute LVEF decline > 10% from baseline to <55% with symptoms of heart failure
Ponde (2018)
[109]
280 T þ L Baseline
2 and 18 weeks after initiation of T
treatment
e Symptomatic heart failure NYHA class III or IV, or cardiac death and secondary cardiac events were
asymptomatic or symptomatic absolute LVEF decline <50% and >10%-points
Goel (2019)
[113]
217 AC þ T Baseline, after AC and every 3 months
during T
e Absolute LVEF decline >15% from baseline, or absolute LVEF decline >10%e50%.
Troponin I Cardinale
(2004) [107]
703 AC þ Tax þ C Soon after chemotherapy and 1 month
after chemotherapy
þ Death with cardiac cause
Acute pulmonary edema
Overt heart failure
Asymptomatic LVEF reduction  25%
Arrhythmias and conduction disturbances requiring a pacemaker
Cardinale
(2002) [115]
211 High dose
chemotherapy
After high dose chemotherapy þ Absolute LVEF decline
Onitilo
(2012) [110]
54 T Baseline vs. every 3 weeks during
1 year T treatment
e Absolute LVEF decline 15% from baseline or an LVEF<50%
Cardinale
(2010) [105]
251 AC þ T Baseline vs. during T treatment þ Absolute LVEF decline >10% from baseline to <50%
Ky (2014)
[106]
78 AC þ T Baseline vs. 3 months after initiation of
AC
þ CREC definition of cardiotoxicity
Putt (2015)
[111]
78 AC þ Tax þ T Baseline vs. every 3 monthse15 months
after start treatment
e CREC definition of cardiotoxicity
59 AC þ L þ T e Maximal absolute LVEF decline (max LVEF emin LVEF/min LVEF) and congestive heart failure
(continued on next page)
N
.I.Bouw
er
et
al./
The
Breast
52
(2020)
33
e
44
39
Table 4 (continued )
Type cardiac
biomarker
Study Number of
patients
Chemotherapy Time point(s) indicative of
cardiotoxicity
Detection of
cardiotoxicity?
Definition cardiotoxicity:
Morris (2011)
[112]
Maximum levels of:
Baseline, 2 months after start AC, 3
months after start AC
Hs-Troponin
T
Kitayama
(2017) [116]
40 AC þ T Baseline vs. during AC and/or T
treatment
þ Absolute LVEF decline >10% from baseline, symptomatic cardiac failure, acute coronary syndrome or
arrhythmias
Zardavas
(2017) [117]
452 AC þ T Baseline þ Absolute LVEF decline of >10% from baseline to <50%
Hs-Troponin
I
Sawaya
(2011) [60]
43 AC þ T Baseline vs. completion of AC treatment þ Absolute LVEF decline of 5% to <55% with symptoms of heart failure or an asymptomatic absolute LVEF
decline 10% to <55%
Sawaya
(2012) [59]
81 AC þ Tax þ T At completion of AC treatment þ Absolute LVEF decline of 5% to <55% with symptoms of heart failure or an asymptomatic absolute LVEF
decline 10% to <55%
Zardavas
(2017) [117]
452 AC þ T Baseline þ Absolute LVEF decline of >10% from baseline to <50%
NT-proBNP Romano
(2011) [118]
71 AC þ Tax þ T Baseline vs. highest value during
chemotherapy
þ Absolute LVEF decline 20% and/or increase in LV end systolic volume 15% from baseline at 3, 6 and 12
months:
Zardavas
(2017) [117]
452 AC þ T Baseline vs. highest value during T
treatment
þ Absolute LVEF decline of >10% from baseline to <50%
Ponde (2018)
[109]
280 L þ T Baseline
2 and 18 weeks after initiation of T
treatment
e Symptomatic heart failure NYHA class III or IV, or cardiac death and secondary cardiac events were
asymptomatic or symptomatic absolute LVEF decline <50% and >10%-points
Ky (2014)
[106]
78 AC þ T Baseline vs. 3 months after initiation of
AC
e CREC definition of cardiotoxicity
Sawaya
(2011) [60]
43 AC þ T 3 months after initiation of AC
treatment
Baseline vs. 3 months after initiation of
AC treatment
e Absolute LVEF decline of 5% to <55% with symptoms of heart failure or an asymptomatic absolute LVEF
decline 10% to <55%
Putt (2015)
[111]
78 AC þ Tax þ T Baseline vs. every 3monthse15months
after start T
e CREC definition of cardiotoxicity
Sawaya
(2012) [59]
81 AC þ Tax þ T Baseline vs. during 1 year follow-up e Absolute LVEF decline of 5% to <55% with symptoms of heart failure or an asymptomatic absolute LVEF
decline 10% to <55%
Fallah-rad
(2011) [108]
42 AC þ T 12 months after initiation of T
treatment
Absolute LVEF decline >10% to <55% with symptoms of congestive heart failure.
Bouwer
(2019) [119]
135 AC þ T Baseline vs. during Treatment e Absolute LVEF decline >10% and/or LVEF <45%
Goel (2019)
[113]
217 AC þ T Baseline, after AC and every 3 months
during T
e Absolute LVEF decline >15% from baseline, or absolute LVEF decline >10%e50%.
hs-CRP Putt (2015)
[111]
78 AC þ Tax þ T Baseline vs. every 3monthse15months
after start T
e CREC definition of cardiotoxicity
Onitilo
(2012) [110]
54 T Maximum values from baseline and
every 3 weeks during 1 year T
þ Absolute LVEF decline 15% from baseline or an LVEF <50%
Ky (2014)
[106]
78 AC þ T Baseline vs. 3 months after initiation of
AC
e CREC definition of cardiotoxicity
CRP Fallah-rad
(2011) [108]
42 AC þ T 12 months after initiation of T
treatment
e Absolute LVEF decline >10% to <55% with symptoms of congestive heart failure.
Morris (2011)
[112]
59 AC þ L þ T Baseline e Maximal absolute LVEF decline (max LVEF emin LVEF/min LVEF) and congestive heart failure
MPO Ky (2014)
[106]
78 AC þ T Baseline vs. 3 months after initiation of
AC
þ CREC definition of cardiotoxicity
Putt (2015)
[111]
78 AC þ Tax þ T Baseline vs. every 3monthse15months
after start T
þ CREC definition of cardiotoxicity
IgE Beer (2016)
[120]
7 AC þ T Baseline þ Absolute LVEF decline 10 from baseline to <50%
ST2 Sawaya
(2012) [59]
81 AC þ T Baseline vs. during 1 year follow-up e Absolute LVEF decline of 5% to <55% with symptoms of heart failure or an asymptomatic absolute LVEF
decline 10% to <55%
Abbreviations: AC, anthracyclineþ cyclophosphamide; T, trastuzumab; L, lapatinib; Tax, taxanes; C, carboplatin; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; CREC, Cardiac Review and Evaluation
Committee.
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N.I. Bouwer et al. / The Breast 52 (2020) 33e44 41hypothesized that inflammation could also have a role in
trastuzumab-induced cardiotoxicity.
A small study of 54 breast cancer patients undergoing trastu-
zumab therapy revealed that normal hs-CRP values may be asso-
ciated with low risk of developing a LVEF decline, thus suggesting
that hs-CRP might have a high negative predictive value (Table 4).
However, multiple other studies could not demonstrate this rela-
tionship [108,111,112].5.4. MPO
Myeloperoxidase (MPO) is a pro-inflammatory enzyme secreted
by polymorph nuclear neutrophils that is involved in lipid peroxi-
dation and released in periods of oxidative stress [130,131]. MPO is
associated with increased risk of cardiac problems such as coronary
artery disease and heart failure exacerbations [132,133]. The po-
tential pathophysiological mechanisms of cardiotoxicity due to
anthracyclines or trastuzumab involves oxidative stress [134].
Therefore, it is biologically plausible that elevated MPO after
anthracycline and trastuzumab therapy can be associated with
cardiotoxicity.
The study of Ky et al. demonstrated that 1 standard deviatio-
nincrease in MPO during anthracycline treatment in patients with
early-staged breast cancer was associated with a 34% increased risk
of subsequent cardiotoxicity [106]. In addition, another study found
that increases in MPO were associated with cardiotoxicity during
anthracycline and trastuzumab treatment [111].5.5. IgE
Immunoglobulin E (IgE) is involved in the immune defense
against parasitic diseases and in the pathogenesis of allergic dis-
eases. IgE is synthesized by plasma cells and the expression is
controlled by two CD4þ T-helper cells: Th1 and Th2 which have
counter-regulatory effects. It is known that the immune system is
involved in maintaining myocardial homeostasis in patients with
heart failure as it influences myocyte hypertrophy andmyocyte loss
through apoptosis [135]. The precise role of the immune system in
trastuzumab-induced cardiotoxicty is yet unknown.
The study of Beer et al. showed that high baseline IgE levels
were associated with a lower risk of cardiotoxicity in patients
treated with anthracyclines and trastuzumab [120]. This suggests
that the immune system may be a potential mediator in car-
diotoxicity caused by anthracyclines or trastuzumab. An interesting
finding which needs further investigation.5.6. ST2
Suppressor of tumorgenicity 2 (ST2) is a member of the inter-
leukin 1 receptor family. It has a transmembrane (ST2L) and a
soluble (sST2) form [136]. As sST2 concentrations reflect cardio-
vascular stress andmyocardial fibrosis, it has become a relative new
prognostic biomarker in both acute and chronic heart failure
[137,138]. Combination of ST2 with other cardiac biomarkers may
improve the prognostic ability of each individual biomarker in
predicting myocardial damage [139]. The 2017 American College of
Cardiology/American Heart Association recommends ST2 in addi-
tion to NT-proBNP as biomarker of myocardial fibrosis or injury for
additive risk stratification [140]. In a small study of 81 patients
treated with anthracyclines and trastuzumab, ST2 levels did not
change during anthracycline and trastuzumab treatment and
measurement of ST2 at completion of anthracyclines did not pre-
dict subsequent development of cardiotoxicity [59].5.7. Summary of different biomarkers
Measuring cardiac biomarkers may also be a potential diag-
nostic tool for early identification of cardiotoxicity. In theory,
biomarker monitoring strategies are less expensive, less time-
consuming for the patient, easier to perform and may possibly
detect myocardial damage at an earlier stage than imaging strate-
gies. However, early identification of patients at high risk for car-
diotoxicity with cardiac biomarkers remains questionable and the
reason why routine assessment of cardiac biomarkers has not yet
been adopted in daily practice. Taken together, measurement of (a
combination of) MPO and hs-troponin seems most promising in
detecting cardiotoxicity in patients treated with anthracyclines
andtrastuzumab. The utility of ST2 and IgE in detecting cardiotox-
icity in these patients has to be additionally studied in order to be
incorporated into clinical practice. Further research is required to
determine the optimal (combination of) biomarker(s), timing of
biomarker analysis and the optimal intervention based on these
biomarker results.6. Summary
Concluding, trastuzumab treatment prolongs progression-free
and overall survival in patients with HER2-positive breast cancer,
but is hampered by cardiotoxicity. Identification of patients at
increased risk of trastuzumab-induced cardiotoxicity is of great
importance to prevent deterioration to irreversible cardiotoxicity.
Nowadays, 3DE seems most suitable for cardiac monitoring of pa-
tients treated with trastuzumab due to the high reproducibility,
high accuracy, the ability to assess the complete cardiac structure
and the possibility to measure strain. Strain measurement with STE
seems promising to detect myocardial damage in an early stage
compared to LVEFmeasurement. However, high quality images and
certain technical requirements are needed to perform STE. In
addition to STE, early signs of myocardial damage could possibly be
detected bymeasuring cardiac biomarkers of which (a combination
of) MPO and hs-troponin are most promising. The optimal fre-
quency of cardiac monitoring during trastuzumab therapy has not
been established yet. Literature indicates that averagely cardiac
monitoring occurs every 3 months during trastuzumab for early-
stage breast cancer and more infrequently during trastuzumab for
advanced-stage breast cancer. The additional value of frequent
cardiac monitoring after discontinuation of trastuzumab has not
been confirmed. To validate the role, frequency and duration of STE
and certain cardiac biomarkers in clinical practice more and larger
studies with clearly defined endpoints in a homogeneous popula-
tion are urgently awaited.Ethical approval
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